- Home
- SENS vs SAGE Comparison
SENS vs SAGE Comparison
Compare SENS & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENS
- SAGE
- Stock Information
- Founded
- SENS 1996
- SAGE 2010
- Country
- SENS United States
- SAGE United States
- Employees
- SENS N/A
- SAGE N/A
- Industry
- SENS Industrial Machinery/Components
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- SENS Industrials
- SAGE Health Care
- Exchange
- SENS Nasdaq
- SAGE Nasdaq
- Market Cap
- SENS 396.0M
- SAGE 413.9M
- IPO Year
- SENS N/A
- SAGE 2014
- Fundamental
- Price
- SENS $0.52
- SAGE $6.46
- Analyst Decision
- SENS Strong Buy
- SAGE Hold
- Analyst Count
- SENS 2
- SAGE 19
- Target Price
- SENS $2.00
- SAGE $9.88
- AVG Volume (30 Days)
- SENS 6.9M
- SAGE 815.0K
- Earning Date
- SENS 05-08-2025
- SAGE 04-29-2025
- Dividend Yield
- SENS N/A
- SAGE N/A
- EPS Growth
- SENS N/A
- SAGE N/A
- EPS
- SENS N/A
- SAGE N/A
- Revenue
- SENS $23,682,000.00
- SAGE $47,404,000.00
- Revenue This Year
- SENS $60.14
- SAGE $103.73
- Revenue Next Year
- SENS $36.55
- SAGE $41.15
- P/E Ratio
- SENS N/A
- SAGE N/A
- Revenue Growth
- SENS 1.64
- SAGE N/A
- 52 Week Low
- SENS $0.25
- SAGE $4.62
- 52 Week High
- SENS $1.40
- SAGE $13.47
- Technical
- Relative Strength Index (RSI)
- SENS 39.02
- SAGE 38.73
- Support Level
- SENS $0.52
- SAGE $6.36
- Resistance Level
- SENS $0.54
- SAGE $6.78
- Average True Range (ATR)
- SENS 0.04
- SAGE 0.24
- MACD
- SENS -0.00
- SAGE -0.01
- Stochastic Oscillator
- SENS 16.29
- SAGE 12.22
About SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.